PP-006

PP-006 is a discontinued drug candidate developed by Primary Peptides, Inc. It is characterized as an epigenetic modulator that functions as an inhibitor of the histone-lysine N-methyltransferase EZH2 (Enhancer of zeste homolog 2). EZH2 is the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), which methylates lysine 27 of histone H3 (H3K27me3) to promote transcriptional silencing. While Primary Peptides utilizes both synthetic peptide and small molecule platforms—including their proprietary CHAPTAC (chaperone-mediated targeted protein degradation) technology—the specific modality and therapeutic indication for PP-006 were not publicly disclosed prior to its discontinuation.